CKM Syndrome
Learning Center
Advancing Care in Cardiovascular-Kidney-Metabolic (CKM) Syndrome
CLOSE
Your Comprehensive Hub For Excellence In CKM Health Education
Through expert interviews, case discussions, expert panels, and patient perspectives, leading global experts deliver the latest evidence-based guidance and real-world experiences for practicing clinicians. Join our growing community of cardiology, nephrology, and metabolic care providers by engaging with the educational content in this learning center and sharing it with your healthcare team.
Together, we can advance the standard of CKM care worldwide!
~ 50 %
of patients with chronic kidney disease (CKD) stages 4 to 5 also have CVD 1
~ 40 %
of individuals with diabetes develop diabetic kidney disease 2
~ 25 %
prevalence of concurrent comorbidities associated with CKM worldwide 3
Educational Programs
Resource Center
Discover a curated collection of foundational, practical, and real-world educational resources at your fingertips. Click on a link to get started.
Maria A. Pabon, Gerasimos Filippatos, Brian L. Claggett, Michael Zi Miao, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Meike Brinker, Patrick Schloemer, Lucas Hofmeister, Li Li, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Peter Rossing, Luis M. Ruilope, Stefan D. Anker, Bertram Pitt, Rajiv Agarwal, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan, Finerenone Reduces New-Onset Atrial Fibrillation across the Spectrum of Cardio-Kidney-Metabolism: the FINE-HEART Pooled Analysis, JACC. 2025, ISSN 0735-1097, https://doi.org/10.1016/j.jacc.2025.03.429.
Matsumoto S, Henderson AD, Jhund PS, et al. Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. Published online March 29, 2025. doi:10.1001/jamacardio.2025.0848
Ostrominski, J, Claggett, B, Causland, F. et al. EFFICACY AND SAFETY OF FINERENONE ACROSS THE SPECTRUM OF KIDNEY RISK IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION. JACC. 2025 Apr, 85 (12_Supplement) 1167.https://doi.org/10.1016/S0735-1097(25)01651-1
Cunningham, J, Claggett, B, Vaduganathan, M. et al. EFFECT OF FINERENONE ON N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION: THE FINEARTS-HF TRIAL. JACC. 2025 Apr, 85 (12_Supplement) 1203.
Desai AS, Jhund PS, Vaduganathan M, et al. Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. Published online March 30, 2025. doi:10.1001/jamacardio.2025.0860
Butt JH, Henderson AD, Jhund PS, et al. Finerenone, obesity, and heart failure with mildly reduced/preserved ejection fraction: prespecified analysis of FINEARTS-HF. J Am Coll Cardiol. 2025;85(2):140-155. doi:10.1016/j.jacc.2024.10.111
Mentz RJ, Anker SD, Pitt B, et al; on behalf of the FIDELIO‐DKD and FIGARO‐DKD Investigators. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. Eur J Heart Fail. Published online January 17, 2025. doi:10.1002/ejhf.3569
Mc Causland FR, Vaduganathan M, Claggett BL, et al. Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial. J Am Coll Cardiol. 2025;85(2):159-168. doi:10.1016/j.jacc.2024.10.091
Solomon SD, McMurray JJV, Vaduganathan M, et al; FINEARTS-HF Committees and Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107
Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777
Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-161. doi:10.1093/eurheartj/ehaa736
Our Faculty
From academia to private practice, leading experts have joined together to advance the standard of CKM care worldwide:
Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Jürgen Floege, MD
Muthiah Vaduganathan, MD, MPH
Scott Solomon, MD
Mikhail Kosiborod, MD
Pardeep Jhund, MD, PhD
Hiddo L. Heerspink, PhD
John McMurray, MD
Akshay S. Desai, MD
Csaba P. Kovesdy, MD
Finnian R. Mc Causland, MD
Orly Vardeny, MD
References:
1. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050686
2. https://www.ncbi.nlm.nih.gov/books/NBK571718/
3. https://www.sciencedirect.com/science/article/abs/pii/S0033062024001488
